- United States
- /
- Medical Equipment
- /
- NasdaqGM:LNTH
Lantheus Holdings (LNTH) Valuation in Focus After Leadership Changes and Raised Revenue Guidance
Reviewed by Simply Wall St
Lantheus Holdings (LNTH) just released its third quarter results, updating annual revenue guidance slightly higher while also announcing significant executive changes. The news arrives as the company moves through a period of management transition.
See our latest analysis for Lantheus Holdings.
Lantheus Holdings has been in the spotlight lately with new leadership moves and guidance updates, but the share price tells a story of mixed momentum. Despite the raised annual outlook and promising pipeline developments, the 1-year total shareholder return is down 31.7%. However, looking back five years, long-term holders have seen a remarkable 341% total return, reflecting substantial value creation even as recent sentiment remains cautious.
Curious where the next dynamic growth stories might come from? This could be the perfect moment to discover See the full list for free.
With shares now trading at a sizable discount to analyst targets and long-term growth visible in its track record, the question becomes whether Lantheus is undervalued or if the market is already factoring in its future prospects.
Most Popular Narrative: 34.4% Undervalued
Lantheus Holdings’ most closely watched narrative sets its fair value far above recent closing prices, challenging the market’s current risk-averse stance. Today’s valuation leaves significant upside implied by these narrative projections if those assumptions play out.
The expansion of Lantheus's Alzheimer's disease imaging franchise, including the recent FDA label expansion for Neuraceq and late-stage tau-targeted radiodiagnostic MK-6240, positions the company to capture accelerating demand driven by broader adoption of amyloid-targeted therapies and increased focus on early diagnosis. This is likely to drive strong revenue growth as the U.S. PET imaging market for Alzheimer's is expected to exceed $1.5 billion by 2030.
Want to know what’s fueling this projection? The secret sauce: big expectations for future revenue momentum, margin expansion, and a transformative shift in earnings power. This combination could turn market skepticism on its head. The specific growth assumptions behind this fair value are not what most investors expect. Unlock the numbers to see what’s really shaping analyst conviction.
Result: Fair Value of $83.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, continued pricing pressure and over-reliance on Pylarify could threaten both revenue growth and earnings stability if competition accelerates and reimbursement headwinds persist.
Find out about the key risks to this Lantheus Holdings narrative.
Build Your Own Lantheus Holdings Narrative
If you see things differently or want to dive into the numbers yourself, it’s quick and easy to shape your own perspective in just a few minutes. Do it your way
A great starting point for your Lantheus Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Smart investors never limit their opportunities. Expand your horizons and amplify your portfolio with handpicked stock ideas before the next big trend takes off.
- Capture potential market-beating gains by jumping in early with these 3575 penny stocks with strong financials that stand out for financial strength and strong fundamentals.
- Maximize your income stream and secure reliable cash flow by tapping into these 14 dividend stocks with yields > 3% with yields over 3%.
- Ride the AI innovation wave by exploring these 25 AI penny stocks reshaping industries with advanced automation and machine learning breakthroughs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:LNTH
Lantheus Holdings
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Undervalued with excellent balance sheet.
Similar Companies
Market Insights
Community Narratives


